BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 15175661)

  • 21. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.
    Josefsson A; Wikström P; Egevad L; Granfors T; Karlberg L; Stattin P; Bergh A
    Scand J Urol Nephrol; 2012 Aug; 46(4):247-57. PubMed ID: 22452635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
    Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
    Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma.
    El-Gohary YM; Silverman JF; Olson PR; Liu YL; Cohen JK; Miller R; Saad RS
    Am J Clin Pathol; 2007 Apr; 127(4):572-9. PubMed ID: 17369132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole-mount prostate sections reveal differential endoglin expression in stromal, epithelial, and endothelial cells with the development of prostate cancer.
    Kassouf W; Ismail HR; Aprikian AG; Chevalier S
    Prostate Cancer Prostatic Dis; 2004; 7(2):105-10. PubMed ID: 15175661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reconsideration of the clinical and histopathological significance of angiogenesis in prostate cancer: Usefulness and limitations of microvessel density measurement.
    Miyata Y; Sakai H
    Int J Urol; 2015 Sep; 22(9):806-15. PubMed ID: 26153072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.
    Fonsatti E; Altomonte M; Nicotra MR; Natali PG; Maio M
    Oncogene; 2003 Sep; 22(42):6557-63. PubMed ID: 14528280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer.
    Lissbrant IF; Lissbrant E; Damber JE; Bergh A
    Scand J Urol Nephrol; 2001 Dec; 35(6):437-52. PubMed ID: 11848422
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 29.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 30.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.